AtriCure (NASDAQ: ATRC) reported Q2 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $71.4 million versus the consensus estimate of $61.07 million.

“Our second quarter results were driven by outperformance across our business, as strong underlying demand returned and we saw continued progress toward making our platforms the standard of care,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We are poised for accelerating growth with the recent FDA approval of our EPi-Sense® System to improve the lives of millions of patients with long-standing persistent Afib. This approval enriches the foundation of our Company, built on core technologies which continue to deliver solid growth as we address vastly underpenetrated markets.”

GUIDANCE:

AtriCure sees FY 2021 revenue of $270-275 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.